Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.4K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.7K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.7K
Acute Coronary Syndrome V: Nursing Management01:26

Acute Coronary Syndrome V: Nursing Management

135
Nursing Assessment:Nursing management of acute coronary syndrome (ACS) involves taking the patient's history, focusing on primary complaints such as chest pain, dyspnea, and excessive sweating (diaphoresis), as well as other symptoms like back or jaw pain, nausea, vomiting, palpitations, dizziness, and fatigue. The nurse also reviews the patient's history of cardiac events, risk factors such as hypertension, diabetes, smoking, family history, and current medications.In the objective assessment,...
135
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

754
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
754
Skeletal Muscle Relaxants: Adverse Effects01:21

Skeletal Muscle Relaxants: Adverse Effects

636
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
636
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

102
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
102

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microglia derived from human induced pluripotent stem cells are regulated by osteopontin, an endogenous extracellular matrix protein maintaining immune homeostasis.

Frontiers in neuroscience·2026
Same author

Phenotype, Severity, and Therapy of Patients With LRP4 Antibody-Associated Myasthenia Gravis in the German Myasthenia Gravis Registry.

Neurology·2026
Same author

Non-ICANS neurotoxicity after BCMA-directed CAR-T therapy: Clinical spectrum, outcomes, and a framework for neurology-oncology co-management.

HemaSphere·2026
Same author

Case Report: B-cell-targeted therapy with ofatumumab achieves remission in refractory panuveitis and coexisting multiple sclerosis.

Frontiers in neurology·2026
Same author

Multicentric prognostic observational study on biomarker profile in immunotherapy-naïve patients with highly active generalized myasthenia gravis (PROGNO-MG): a study protocol.

Neurological research and practice·2026
Same author

ActIIR inhibition improves motor outcome and preserves muscle fibers after experimental autoimmune neuritis.

Acta neuropathologica communications·2026

Related Experiment Video

Updated: Nov 25, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.6K

SOP myasthenic crisis.

Henning Stetefeld1, Michael Schroeter1

  • 1Department of Neurology, University of Cologne, Kerpener Str. 62, 50937 Cologne, Germany.

Neurological Research and Practice
|December 16, 2020
PubMed
Summary
This summary is machine-generated.

Myasthenic crisis (MC) is a severe manifestation of myasthenia gravis (MG) requiring intensive care. Early diagnosis and treatment, including airway management and immunotherapies, are crucial for preventing fatal outcomes.

More Related Videos

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.9K
Utilizing the Modified T-Maze to Assess Functional Memory Outcomes After Cardiac Arrest
07:02

Utilizing the Modified T-Maze to Assess Functional Memory Outcomes After Cardiac Arrest

Published on: January 5, 2018

12.4K

Related Experiment Videos

Last Updated: Nov 25, 2025

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

5.6K
Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
08:56

Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation

Published on: September 24, 2021

2.9K
Utilizing the Modified T-Maze to Assess Functional Memory Outcomes After Cardiac Arrest
07:02

Utilizing the Modified T-Maze to Assess Functional Memory Outcomes After Cardiac Arrest

Published on: January 5, 2018

12.4K

Area of Science:

  • Neurology
  • Critical Care Medicine

Background:

  • Myasthenic crisis (MC) is a rare but life-threatening complication of myasthenia gravis (MG), characterized by rapid respiratory and bulbar muscle weakness.
  • While the overall prevalence of MC is low, 15-20% of MG patients experience at least one crisis, often within the first two years of diagnosis or as an initial symptom.
  • MC necessitates mechanical ventilation and intensive care, with a median ventilation duration of 2 weeks, though prolonged courses are common due to comorbidities.

Purpose of the Study:

  • To outline the critical management strategies for myasthenic crisis.
  • To emphasize the importance of early diagnosis and intervention in improving patient outcomes.

Main Methods:

  • Clinical assessment and history taking to identify red flags and symptom progression.
  • Intensive care unit admission for monitoring and respiratory support.
  • Initiation of symptomatic and causal treatments, including immunotherapies.

Main Results:

  • Rapidly progressive respiratory and bulbar muscle weakness are key indicators of impending MC.
  • Early intubation is essential for airway protection in cases of aspiration or respiratory insufficiency.
  • Symptomatic treatment (pyridostigmine/neostigmine) combined with acute causal therapies (immunoadsorption/plasmapheresis/immunoglobulins) can lead to rapid clinical improvement.

Conclusions:

  • Prompt diagnosis and management of MC, including airway securing and appropriate therapies, are vital for patient survival.
  • Optimizing immunosuppression (corticosteroids, azathioprine) and managing complications like infections and delirium are crucial for long-term outcomes.
  • While MC itself is rarely fatal, comorbidities and complications significantly influence mortality rates.